Close

News

TraceLink Unveils Industry Speakers for FutureLink Munich

TraceLink Inc., the World's Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, announced the latest industry speakers confirmed for FutureLink Munich, which will occur June 6-7,...

Final results from landmark DYNAGITO® trial published in The Lancet Respiratory Medicine

Boehringer Ingelheim announced data from the landmark 52-week DYNAGITO® trial which show that in people with COPD (chronic obstructive pulmonary disease), Spiolto®Respimat® (tiotropium/olodaterol 5/5µg) lowers the rate of moderate-to-severe exacerbations compared with Spiriva® Respimat® (tiotropium). The...

Aptar Pharmaleadsthe organization of the 7th Innovative Drug Delivery Solutions Symposium 2018, Hangzhou, China

Aptar Pharma, a leading drug delivery systems provider, is proud to announce its leading role in the organization of the forthcoming 7th Innovative Drug Delivery Solutions Symposium (IDDS). The biennial conference is to be held this year at the...

Aptar Pharma to Showcase Next Generation of Integrated Connected Devices at RDD 2018 Arizona

Aptar Pharma, a leading global solution provider of innovative drug delivery systems, is pleased to be a Platinum Sponsor at RDD 2018, taking place from April 22 to April 26 at the JW Marriott Starr Pass Resort and Spa,Tucson,...

Vetter wins 2018 ISPE Facility of the Year Award

Vetter has won the 2018 ISPE Facility of the Year Award (FOYA) in the Facility of the Future category for its Center for Visual Inspection and Logistics. The renowned prize is awarded annually by the prominent industry...

Pradaxa®’s Favourable safety profile (dabigatran etexilate) confirmed in large prospective real-world analysis

New data from one of the largest prospective ongoing global studies examining the use of oral antithrombotics for stroke prevention in atrial fibrillation (AF) in clinical practice, GLORIATM-AF, were presented at the EHRA 2018, the annual congress of the...

Orchard Therapeutics Strengthens Executive Leadership Team with Appointment of Chief Commercial Officer and General Counsel

Orchard Therapeutics, a clinical-stage biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, announced two key additions to its executive leadership team, appointing Jason Meyenburg as chief commercial officer and John Ilett...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »